Advanced Solid Tumors Clinical Trials in Pittsburgh, Pennsylvania

4 studies are recruiting for advanced solid tumors in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

    The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    Locations
    22 in total
    Run by
    Pyxis Oncology, Inc

    See if you can join NCT06795412 on ClinicalTrials.gov

  2. An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Dete…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Teva Investigational Site 12058, Pittsburgh, Pennsylvania
    Locations
    12 in total
    Run by
    Teva Branded Pharmaceutical Products R&D LLC

    See if you can join NCT06480552 on ClinicalTrials.gov

  3. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

    This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania
    Locations
    11 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT06413680 on ClinicalTrials.gov

  4. A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

    The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
    Locations
    4 in total
    Run by
    AskGene Pharma, Inc.

    See if you can join NCT05867420 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.